Xifu Liu
Professor & Director for The Center of Drug Discovery and Innovation at Hebei Normal University- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Experience
-
Hebei Normal University
-
China
-
Higher Education
-
1 - 100 Employee
-
Professor & Director for The Center of Drug Discovery and Innovation
-
Dec 2017 - Present
1. Start-up research center to focus on drug discovery and innovation by using State of Art Technologies for drug screening , computer based design and biological assays. 2. Close collaboration with global academic and industrial experts. 1. Start-up research center to focus on drug discovery and innovation by using State of Art Technologies for drug screening , computer based design and biological assays. 2. Close collaboration with global academic and industrial experts.
-
-
-
Zhangjiakou Jianlong Health Fund and Jianyuan Tech. Co. Ltd.
-
Zhangjiakou, Hebei, China
-
Founder
-
Dec 2017 - Present
1. Have Raised significant funds to invest early to mid stage companies for health industry ; 2. Founder of two companies focusing on food safety testing and precision medicine products and technologies 1. Have Raised significant funds to invest early to mid stage companies for health industry ; 2. Founder of two companies focusing on food safety testing and precision medicine products and technologies
-
-
-
Zensun (Shanghai) Sci. & Tech. Co. ltd
-
Pudong, Shanghai, China
-
EXecutive VP
-
2000 - Dec 2017
Innovative drug development for Chronic Heart Failure and Cancer Innovative drug development for Chronic Heart Failure and Cancer
-
-
-
Zensun USA INC
-
Greater San Diego Area
-
President
-
Nov 2006 - Aug 2016
1) Establishing Zensun USA, a wholly-owned subsidiary of its Parent Company, Zensun (Shanghai); 2) Building and overseeing core team of Zensun USA for clinical, CMC, Regulatory and QA functions; 3) Filing TGA and FDA IND for a phase 2 clinical program for the treatment of CHF; 4) Overseeing clinical trials in Australia and USA; 5) Organizing EOP2 meeting with FDA for phase 3 clinical development 1) Establishing Zensun USA, a wholly-owned subsidiary of its Parent Company, Zensun (Shanghai); 2) Building and overseeing core team of Zensun USA for clinical, CMC, Regulatory and QA functions; 3) Filing TGA and FDA IND for a phase 2 clinical program for the treatment of CHF; 4) Overseeing clinical trials in Australia and USA; 5) Organizing EOP2 meeting with FDA for phase 3 clinical development
-
-
-
Victor Chang Cardiac Research Institute
-
Australia
-
Research
-
100 - 200 Employee
-
Postdoc/Senior Research Officer
-
Jul 1996 - Nov 2000
-
-
Education
-
Institute of Genetics, CAS
Doctor of Philosophy (PhD), Molecular Genetics -
Beijing Medical University/Institute Genetics, CAS
Master's degree, Cytogenetics/cancer genetics -
Hebei Normal University
Bachelor of Science (BSc), Biology